NeoGenomics, Inc. (OTC BB: NGNM)

NeoGenomics, Inc. is a high-complexity, clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company services oncologists, pathologists, and hospitals throughout the United States and offers four primary types of testing services: FISH testing (Fluorescence in situ Hybridization), which analyzes abnormalities at the gene level; cytogenetics testing, which analyzes human chromosomes; flow cytometry testing, which analyzes clusters of differentiation on cell surfaces, and molecular testing, which analyzes abnormalities in DNA. NeoGenomics state-of-the-art genetic testing is provided at three facilities in Ft. Myers, Florida; Nashville, Tennessee; and Irvine, California. Each of NeoGenomics’ laboratories is fully licensed under the Clinical Laboratories Improvement Act, as amended (CLIA), and is accredited by the College of American Pathology (CAP). NeoGenomics is competitive through intense client focus, differentiated products and markedly faster turnaround times.